Evidence map›Paper›PMID 36417109›Full record

ArticleApplied biochemistry and biotechnology2023

Delivery of Fc-fusion Protein by a Recombinant Newcastle Disease Virus Vector.

Zenglei Hu, Jianing Feng, Jing Deng, Yanyan Zhang, Xiaozheng He, Jiao Hu, Xiaoquan Wang, Shunlin Hu, Xiaowen Liu, Xiufan Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Applied biochemistry and biotechnology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 79% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Zenglei Hu *Joint International Research Laboratory of Agriculture and Agri-Product Safety, The Ministry of Education of China, Yangzhou University, Yangzhou, China.ORCID http://orcid.org/0000-0002-8102-595X
Jianing Feng *Joint International Research Laboratory of Agriculture and Agri-Product Safety, The Ministry of Education of China, Yangzhou University, Yangzhou, China.
Jing DengJoint International Research Laboratory of Agriculture and Agri-Product Safety, The Ministry of Education of China, Yangzhou University, Yangzhou, China.
Yanyan ZhangJoint International Research Laboratory of Agriculture and Agri-Product Safety, The Ministry of Education of China, Yangzhou University, Yangzhou, China.
Xiaozheng HeJoint International Research Laboratory of Agriculture and Agri-Product Safety, The Ministry of Education of China, Yangzhou University, Yangzhou, China.
Jiao HuAnimal Infectious Disease Laboratory, School of Veterinary Medicine, Yangzhou University, Yangzhou, China.
Xiaoquan WangAnimal Infectious Disease Laboratory, School of Veterinary Medicine, Yangzhou University, Yangzhou, China.
Shunlin HuAnimal Infectious Disease Laboratory, School of Veterinary Medicine, Yangzhou University, Yangzhou, China.
Xiaowen LiuAnimal Infectious Disease Laboratory, School of Veterinary Medicine, Yangzhou University, Yangzhou, China.
Xiufan LiuAnimal Infectious Disease Laboratory, School of Veterinary Medicine, Yangzhou University, Yangzhou, China. xfliu@yzu.edu.cn.
Yangzhou University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fc-fusion proteins (FCPs), a new generation biological medicine, have revolutionized the practice of medicines that treat diseases. However, complex manufacturing techniques are required for FCP production, casting the affordability and accessibility issues in low- and middle-income economies (LMIEs). Virus-vectored system may serve as a simple and cost-effective platform for FCP delivery. As a proof-of-concept study, Newcastle disease virus (NDV), a widely-used vector for vaccine generation, was used as a vector to express and deliver a model FCP composed of the hemagglutinin (HA) and IgG Fc. A recombinant NDV expressing the HA-Fc fusion protein was generated using reverse genetics, which had comparable replication and virulence to the parental virus. High levels of expression of soluble HA-Fc were detected in cell culture and embryonated chicken eggs inoculated with the recombinant NDV. In addition, the recombinant NDV replicated in the lung of mouse, delivering the HA-Fc protein to this organ. The HA-Fc expressed by NDV specifically bound to murine FcγRI, which was dependent on the presence of the Fc tag. The recombinant NDV induced high vector-specific antibody response, whereas it failed to elicit H7N9-specific antibody immunity in mice. The absence of HA-specific antibodies may be attributed to deficient incorporation of the HA-Fc protein into NDV virion particles. Our results indicated that NDV may be potentially used as a vector for FCP expression and delivery. This strategy may help to enhance the affordability and equal accessibility of FCP biological medicines, especially in LIMEs.

Indexed as

Influenza A Virus, H7N9 SubtypeInfluenza in BirdsNewcastle DiseaseViral VaccinesAnimalsAntibodiesAntibodies, ViralChickensMiceNewcastle disease virusRecombinant ProteinsAntibodiesAntibodies, ViralRecombinant ProteinsViral VaccinesDeliveryExpressionFc-fusion proteinNewcastle disease virusVirus vector

Identifiers

PMID36417109
OpenAlexW4309715019

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.